Delivery Order SPE2DB25D3020-SPE2DB25FWHLV
Award Date 5/12/25
Potential Completion Date 6/3/25
Potential Value $35K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a $24,673.08 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HEMLIBRA 105 mg/0.7 ml vials on September 19, 2025, with an ultimate completion date of October 10, 2025. This non-competitive delivery order is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HEMLIBRA is a specialty pharmaceutical product used in hemophilia treatment, reflecting the federal government's need for advanced therapeutic...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $24,673.08 to AmerisourceBergen Drug Corp for the supply of HEMLIBRA 105 mg/0.7 ml vials. This is a firm fixed-price, non-set-aside contract with a completion date of August 8, 2025, and was awarded on July 18, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order operates under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- The Defense Logistics Agency awarded a $24,673.08 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Hemlibra 105 mg/0.7 ml vials. This is a firm fixed-price delivery order with a completion date of September 2, 2025, and will be performed at the vendor's location in Conshohocken, Pennsylvania. The award carries no set-aside designation, indicating it was competitively awarded. Hemlibra is a specialty pharmaceutical product used in the treatment of hemophilia,...
- The Defense Logistics Agency awarded a $24,673.08 delivery order to AmerisourceBergen Drug Corp for Hemlibra 105 mg/0.7 mL vials. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of September 24, 2025. Hemlibra is a specialized biopharmaceutical used in the treatment of hemophilia, reflecting the critical nature of pharmaceutical procurement for military and federal healthcare systems. The place of performance is AmerisourceBergen's corporate headquarters in...
- This federal contract award, valued at $16,704.72, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of HEMLIBRA 150 MG/ML VIALML. The contract is a Delivery Order with a Firm Fixed Price pricing type and an ultimate completion date of August 5, 2024. Amerisourcebergen Drug Corp, through its Corporate Office Division, has a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- This is a $24,673.08 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Hemlibra 105 mg/0.7 ml vials, a specialty medication. There is no set-aside designation, indicating this was an open competition. The contract has an ultimate completion date of March 31, 2025. AmerisourceBergen holds a larger $999,999,999 Indefinite Delivery...
- This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The $12,336.54 firm fixed-price delivery order is for the supply of HEMLIBRA 105 MG/0.7 ML VIAL 0.7ML, a specialty medication. The contract has an ultimate completion date of March 28, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
- This federal contract award, with an ID of SPE2DB22D3301|SPE2DB25FX4KD, was issued by the Defense Logistics Agency (DLA) for the delivery of HEMLIBRA 150 MG/ML VIALML, a specialty pharmaceutical product. The $16,704.72 firm-fixed-price delivery order has an ultimate completion date of November 18, 2024 and was awarded on October 25, 2024 to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is not set aside for any specific business...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corporation's Corporate Office Division. The $16,704.72 firm-fixed-price delivery order is for the supply of Hemlibra, a prescription medication, with a completion date of September 10, 2024. This award does not have a set-aside designation. Amerisourcebergen is a major pharmaceutical distributor that holds several indefinite-delivery contracts (IDCs) with DLA and other federal agencies to...
- The Defense Logistics Agency awarded a delivery order valued at $7,613.15 to AmerisourceBergen Drug Corp on August 1, 2025, for 2,400 units of HUMATE-P VWF:RCOS with an ultimate completion date of August 22, 2025. This firm fixed-price, competitively awarded contract represents a non-set-aside delivery order executed under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 global pharmaceutical support vehicle running through...